Brentuximab vedotin (Adcetris, Seattle Genetics) can be an antibody-drug conjugate (ADC) that joins an anti-CD 30 monoclonal antibody with the anti-tubulin agent monomethyl auristatin E, via a dipeptide linker. like a lymphoproliferative disorder until recently [1]. Hodgkin lymphoma is definitely divided into classical HL (cHL) and nodule lymphocyte-predominant HL (NLPHL), with the former becoming overwhelmingly… Continue reading Brentuximab vedotin (Adcetris, Seattle Genetics) can be an antibody-drug conjugate (ADC)